Chicago Capital LLC Makes New $270,000 Investment in NeoGenomics, Inc. (NASDAQ:NEO)

Chicago Capital LLC bought a new stake in NeoGenomics, Inc. (NASDAQ:NEO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 16,380 shares of the medical research company’s stock, valued at approximately $270,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp increased its holdings in NeoGenomics by 1.6% in the third quarter. State Street Corp now owns 4,958,582 shares of the medical research company’s stock valued at $73,139,000 after purchasing an additional 80,449 shares during the last quarter. Geode Capital Management LLC grew its position in shares of NeoGenomics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock worth $45,022,000 after buying an additional 36,136 shares during the period. Franklin Resources Inc. raised its position in shares of NeoGenomics by 2.0% in the 3rd quarter. Franklin Resources Inc. now owns 2,043,840 shares of the medical research company’s stock valued at $28,225,000 after acquiring an additional 39,740 shares during the period. Segall Bryant & Hamill LLC boosted its stake in NeoGenomics by 67.0% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company’s stock worth $27,928,000 after acquiring an additional 759,524 shares during the last quarter. Finally, Bellevue Group AG boosted its stake in NeoGenomics by 34.2% during the 3rd quarter. Bellevue Group AG now owns 1,612,612 shares of the medical research company’s stock worth $23,786,000 after acquiring an additional 410,516 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

Shares of NEO stock opened at $13.88 on Tuesday. NeoGenomics, Inc. has a 12 month low of $12.13 and a 12 month high of $19.11. The company’s fifty day simple moving average is $16.46 and its 200-day simple moving average is $15.70. The firm has a market cap of $1.78 billion, a PE ratio of -22.75 and a beta of 1.23. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. The firm had revenue of $167.80 million for the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.06) EPS. Equities research analysts expect that NeoGenomics, Inc. will post -0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on NEO. Benchmark lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Jefferies Financial Group started coverage on NeoGenomics in a research note on Tuesday, December 10th. They set a “buy” rating and a $22.00 price objective on the stock. The Goldman Sachs Group decreased their target price on NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Friday, January 10th. Finally, Bank of America boosted their price objective on NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.20.

Insider Buying and Selling

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the sale, the general counsel now directly owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. This represents a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.